Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing–remitting multiple sclerosis patients: a monocentric longitudinal observational study
Chiara Zanetta, Maria A. Rocca, Alessandro Meani, et al.
Journal of Neurology (2023) Vol. 270, Iss. 7, pp. 3553-3564
Open Access | Times Cited: 18

Showing 18 citing articles:

Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis
Rosa Cortese, Giovanna Testa, Francesco Assogna, et al.
CNS Drugs (2024) Vol. 38, Iss. 4, pp. 267-279
Open Access | Times Cited: 4
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
Seraj Makkawi, Ahmad Abulaban, Yaser Al Malik, et al.
Neurology and Therapy (2025)
Open Access
Identifying Cladribine prescription pattern in MS: an Italian multicentre study
Aurora Zanghì, Roberta Fantozzi, Matteo Foschi, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Additional Cladribine Tablets Treatment Courses in Multiple Sclerosis Patients. A Retrospective Observational Study in Latin American Countries
Berenice Silva, María Célica Ysrraelit, Gisela Zanga, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106275-106275
Closed Access
CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis
Damiano Marastoni, Matteo Foschi, Chiara Eccher, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France
Jonathan Ciron, Bertrand Bourre, Giovanni Castelnovo, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 3, pp. 503-518
Open Access | Times Cited: 1
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 6
Open Access | Times Cited: 1
Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine
Elisabetta Signoriello, Matteo Foschi, Roberta Lanzillo, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 4039-4045
Open Access | Times Cited: 1
Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy
Massimo Filippi, Laura Ferrè, Chiara Zanetta, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 1
A case report of cladribine‐induced IgG4-associated liver injury
Marco Biolato, Assunta Bianco, Maria Cristina Giustiniani, et al.
Acta Neurologica Belgica (2024)
Closed Access | Times Cited: 1
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing
Alessia Manni, Florian Oggiano, C. Palazzo, et al.
Journal of the Neurological Sciences (2024) Vol. 462, pp. 123070-123070
Open Access | Times Cited: 1
Safety of high efficacy therapies in older people with Multiple Sclerosis: a real-world evidence study
Berenice Silva, Federico Casales, Claudia Burbano Donoso, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 90, pp. 105830-105830
Closed Access | Times Cited: 1
New autoimmune disorder development after immune reconstitution therapy for multiple sclerosis
Nataša Giedraitienė, Rasa Kizlaitienė, Gintaras Kaubrys
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness
Berenice Silva, Alejandra Heriz, Jeremías Ayerbe, et al.
Neurological Sciences (2024)
Closed Access
Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy
Roberto Bergamaschi, Marco Capobianco, Roberto Ravasio
AboutOpen (2024) Vol. 11, Iss. 1, pp. 48-56
Open Access
Real-world effectiveness of cladribine as an escalation strategy for MS: Insights from the Czech nationwide ReMuS registry
Pavel Potužník, Jiří Drahota, Dana Horáková, et al.
Journal of Central Nervous System Disease (2024) Vol. 16
Open Access
New autoimmune disorders after Immune Reconstitution Therapy for Multiple Sclerosis
Nataša Giedraitienė, Rasa Kizlaitienė, Gintaras Kaubrys
Research Square (Research Square) (2024)
Open Access
Cladribine

Reactions Weekly (2023) Vol. 1985, Iss. 1, pp. 160-160
Closed Access
Page 1

Scroll to top